BIOFILCHEM36.00

Biofil Chemicals & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMANGALAMVINEETLABLASAORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹58.6 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
BIOFILCHEM
FY26
MANGALAM
FY26
VINEETLAB
FY26
LASA
FY26
Peer
Median
Valuation — at last close
P/E21.05×36.00×36.00× -42%
P/B2.72×0.54×1.52×0.69×0.69× +294%
EV/EBITDA94.77×-10.74×11.53×-1.54×-1.54× +6270%
Market Cap₹58.6 Cr₹55.2 Cr₹69.2 Cr₹34.2 Cr₹55.2 Cr +6%
Growth
Revenue CAGR 3Y-1.85%-34.59%-42.11%-38.35% +95%
Revenue CAGR 5Y-4.50%-24.58%-34.11%-29.34% +85%
Net Income CAGR 3Y70.67%8.59%8.59% +723%
Revenue YoY (latest Q)91.99%-0.40%34.21%-93.87%-0.40% +23098%
Net Income YoY (latest Q)-95.47%44.64%111.58%83.05%83.05% -215%
Profitability
EBITDA Margin2.29%-6.42%14.27%-112.98%-6.42% +136%
Net Income Margin9.81%-19.13%2.70%-135.60%-19.13% +151%
Return on Common Equity12.92%-43.08%3.52%-68.70%-43.08% +130%
Return on Capital Employed1.70%-27.98%10.55%-69.54%-27.98% +106%
Return on Assets6.50%-14.10%1.29%-51.44%-14.10% +146%
Credit & Quality
Total Debt/Equity0.14×1.02×0.99×0.20×0.99× -86%
Interest Coverage37.37×-2.04×1.24×-89.13×-2.04× +1932%
Scale — latest FY
Revenue / Total Income₹28.4 Cr₹232 Cr₹59.4 Cr₹25.1 Cr₹59.4 Cr -52%
Net Income₹2.8 Cr−₹44.4 Cr₹1.6 Cr−₹34.1 Cr−₹34.1 Cr +108%
Total Assets₹42.8 Cr₹315 Cr₹125 Cr₹66.3 Cr₹125 Cr -66%
EPS₹1.71₹-28.05₹1₹-6.8₹-6.8 +125%
Book Value per Share₹13.25₹65.11₹23.74₹9.9₹23.74 -44%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.